Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 16/20 | 0.76 |
| ▸ | ADRA2B | P18089 | 15/20 | 0.76 |
| ▸ | ADRA2C | P18825 | 15/20 | 0.76 |
| ▸ | PTGIR | P43119 | 3/20 | 0.61 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13017196 | 0.86 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL13017291 | 0.86 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL13017221 | 0.83 | ADRA2A (0.76) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL13017287 | 0.81 | ADRA2A (0.79) | ADRA2AADRA2BADRA2CPTGIRADRA1D | |
| SCHEMBL13017193 | 0.81 | ADRA2A (0.88) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL13062961 | 0.81 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL4689733 | 0.80 | ADRA2A (0.85) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL4690804 | 0.80 | ADRA2A (0.85) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| Hydrochloric Acid SCHEMBL4686622 | 0.78 | ADRA2A (0.82) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL13985246 | 0.77 | ADRA2A (0.79) | ADRA2AADRA2BADRA2CPTGIRADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1286673-B8 | LIGANDS OF INTEGRIN RECEPTORS | ABBOTT GMBH & CO KG (DE) | 2005-07-20 | — | — | EP | disclosed |
| EP-1286673-B1 | LIGANDS OF INTEGRIN RECEPTORS | BASF AG (DE) | 2005-05-25 | — | — | EP | disclosed |
| EP-1286673-A2 | LIGANDS OF INTEGRIN RECEPTORS | Basf Aktiengesellschaft (DE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001093840-A2 | LIGANDS OF INTEGRIN RECEPTORS | BASF AG (DE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | ADRA2A 337/4885ADRA2B 300/4885ADRA2C 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.